Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

PBLSBullishIndustry Newsnews

High materiality8/10

Parabilis PBLS: strong ESMO data push desmoid program toward Phase 3

Oct 24, 2026, 9:41 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Robust early efficacy (ORR 72.2%, DCR 100%), favorable safety, and FDA-aligned registrational plan reduce execution risk and may justify a higher multiple as Phase 3 progresses.

AI summary

What happened, with direct paths to the underlying reporting

Parabilis Medicines reported updated Phase 1/2 data for zolucatetide at ESMO 2026, showing a 72.2% ORR and 100% DCR at starting doses ≥450 mg. The company confirmed a 450 mg weekly induction for four cycles followed by 300 mg every two weeks for maintenance, and alignment with FDA on registrational design, with a Phase 3 PEDESTAL trial slated to begin in H1 2027 and topline results in 2029.

Zolucatetide shows desmoid tumor efficacy; ORR 72.2% and DCR 100% at ≥450 mg.
FDA alignment on dose, regimen, placebo control, and PFS for registrational path.
Phase 3 PEDESTAL planned H1 2027; topline results anticipated in 2029.
76 patients enrolled; median age 37; 69.7% female; includes prior GSI exposure.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.